. Author manuscript; available in PMC: 2013 Nov 1.

Published in final edited form as: Cancer Causes Control. 2012 Sep 8;23(11):1805–1810. doi: 10.1007/s10552-012-0059-y

Table 2.

Table 2a ABO blood group and risk of ovarian cancer in 8 studies from the Ovarian Cancer Association Consortium
Blood group	MAY^a	NCO^a	NEC^b	NHS^c	POL^a	TBO^a	TOR^a	UKG^d	meta-analysis^f

	OR	OR	OR	OR	OR	OR	OR	OR	Cases (N)	Controls (N)	OR	(95% CI)	p
O	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2222	2987	1.00	(ref.)
A	1.21	1.04	1.10	0.92	1.03	1.67	1.23	1.07	2286	2865	1.09	(1.01–1.18)	0.03
B	0.95	1.21	1.26	0.89	0.66	1.59	1.14	0.93	529	732	1.03	(0.88–1.20)	0.76
AB	0.78	1.13	1.03	1.48	0.86	0.69	1.28	1.21	195	253	1.09	(0.89–1.33)	0.40

Table 2b ABO diplotype and risk of ovarian cancer in 8 studies from the Ovarian Cancer Association Consortium
Diplotype	MAY^a	NCO^a	NEC^b	NHS^c	POL^a	TBO^a	TOR^a	UKG^d	meta-analysis^f

	OR	OR	OR	OR	OR	OR	OR	OR	Cases (N)	Controls (N)	OR	(95% CI)	p
O/O	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2222	2987	1.00	(ref.)
A/O	1.35	0.98	1.14	0.95	0.95	1.71	1.26	1.09	1912	2363	1.11	(1.01–1.22)	0.03
A/A	0.67	1.37	0.93	0.74	1.36	1.58	1.09	0.99	374	502	1.03	(0.87–1.21)	0.76
B/O	0.95	1.15	1.23	0.88	0.67	1.69	1.17	0.95	495	681	1.09	(0.88–1.19)	0.73
B/B	0.94	2.85	1.76	0.96	0.61	NA^e	0.89	0.53	34	51	0.98	(0.61–1.56)	0.92
A/B	0.78	1.13	1.03	1.48	0.86	0.69	1.28	1.21	195	253	1.09	(0.89–1.33)	0.40

Adjusted for age

Adjusted for age and study phase

Adjusted for age, DNA source (blood vs. cheek) and cohort (NHS vs. NHSII)

Unadjusted

There were no cases with the BB diplotype.

Results were combined using random-effects meta-analysis; all p-heterogeneity across studies were >0.20